Gene therapy holds great promise for the treatment of various genetic diseases. However, successes in expressing transgenes in vitro are often not reproduced when transferred in vivo. It became clear in several studies that immune responses to the vector and/or transgene product heavily influence in vivo gene therapy oerformance. The Immunology Core has focused its efforts on studying the natural existing T and B cell mmunity to Adenovirus (AdV) and Adeno-associated virus (AAV) in human and non human primates (NHPs). We have also .centered our studies on vector and transgene specific T and B cell responses after systemic or local administration of various rAAV and rAdV serotypes carrying different transgenes in NHP models. This will help us to determine if rAAV and rAdV administration can re-activate existing or induce new T cell responses to the vector or the transgene product, and whether these have any effect on the outcome of the gene therapy and the health of the patient. Moreover we studied the activation of hCFTR-specific T cells in cystic fibrosis mice following gene transfer. The mission of the Immunology Core is to assist Center Participants in developing and conducting assays to evaluate cell mediated and humoral immune responses after gene therapy treatment in small and large animal models including mice, dogs, non human primates and humans. In all these studies we isolated lymphocytes from blood, liver, intestine, primary and secondary lymphoid organs and characterized the T cell response by ex vivo and cultured IFNy ELISPOT, lymphoproliferation assay, in vivo CTL assay, and polychromatic flow cytometric analysis (5-11 colors) of antigen specific T cells. B cell responses were characterized measuring total and neutralizing antibodies in serum and mucosal secretions.
Undesirable immune response to viral vectors and therapeutic gene products could affect the outcome of gene therapy. Immunology Core is well-equipped and determined to investigate this problem in pre-clinical and clinical gene therapy studies.
|Svidritskiy, Egor; Korostelev, Andrei A (2018) Conformational Control of Translation Termination on the 70S Ribosome. Structure 26:821-828.e3|
|Svidritskiy, Egor; Korostelev, Andrei A (2018) Mechanism of Inhibition of Translation Termination by Blasticidin S. J Mol Biol 430:591-593|
|McClain, Lauren E; Davey, Marcus G; Zoltick, Phillip W et al. (2016) Vector serotype screening for use in ovine perinatal lung gene therapy. J Pediatr Surg 51:879-84|
|Calcedo, Roberto; Wilson, James M (2016) AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. Hum Gene Ther Clin Dev 27:79-82|
|Gurda, Brittney L; De Guilhem De Lataillade, Adrien; Bell, Peter et al. (2016) Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol Ther 24:206-216|
|Svidritskiy, Egor; Madireddy, Rohini; Korostelev, Andrei A (2016) Structural Basis for Translation Termination on a Pseudouridylated Stop Codon. J Mol Biol 428:2228-36|
|Greig, Jenny A; Calcedo, Roberto; Grant, Rebecca L et al. (2016) Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine 34:6323-6329|
|Svidritskiy, Egor; Korostelev, Andrei A (2015) Ribosome Structure Reveals Preservation of Active Sites in the Presence of a P-Site Wobble Mismatch. Structure 23:2155-61|
|Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87|
|Calcedo, Roberto; Franco, Judith; Qin, Qiuyue et al. (2015) Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. Hum Gene Ther Methods 26:103-5|
Showing the most recent 10 out of 231 publications